Telmisartan raw powder is an angiotensin II receptor blocker that can play a hypotensive role, mainly used in patients with hypertension, and can also reduce the risk of cardiovascular disease.
Clinical commonly used preparations are telmisartan, such as telmisartan capsules, telmisartan hydrochlorothiazide tablets, and telmisartan hydrochlorothiazide capsules. Angiotensin is the main vasopressor of the renin angiotensin system, which helps to contract blood vessels, promote aldosterone synthesis and release, and improve the reabsorption of sodium by the kidney. After using telmisartan preparation, it can inhibit the vasoconstriction of angiotensin and the secretion of aldosterone, playing a hypotensive role. Telmisartan preparations are mainly excreted through bile. Patients with biliary obstructive diseases or liver dysfunction may have a relatively low clearance rate for the drug and may experience cholestasis, so it should be used with caution. If the patient must use this drug, they can start using it at a small dose, while slowly adjusting the treatment dose to reduce the chance of adverse reactions.
Irbesartan raw powder is a commonly used oral antihypertensive drug, belonging to the ARB class. It mainly inhibits the binding of angiotensin and receptor 1, thereby inhibiting angiotensin mediated vasoconstriction and dilation, and playing a hypotensive role. Irbesartan, an ARB antihypertensive drug, is mainly used for primary hypertension. At the same time, because Irbesartan itself has certain renal protection, it can also be used for the treatment of type 2 diabetes nephropathy patients with hypertension. The absorption of irbesartan after oral administration is not affected by food. You can choose to take irbesartan before meals or after meals. The specific time of taking irbesartan can be at any time of the day, such as taking it regularly in the morning or at night. Erbesartan is mainly excreted through the liver, gallbladder, and feces in the body, with a small amount excreted through the kidneys. Therefore, patients with renal dysfunction do not need to adjust the dose, and patients with mild to moderate liver dysfunction can also use it. It is important to remember that irbesartan should be carefully used in pregnant and lactating women.
Although both drugs belong to the sartan class of antihypertensive drugs, the indications of the two drugs are also different.
Telmisartan can reduce the risk of cardiovascular disease hospitalization and death for high-risk groups, such as patients with coronary heart disease, myocardial infarction, stroke and diabetes.
Irbesartan has sufficient evidence-based medical research in reducing urinary protein and delaying deterioration of renal function, so it is more suitable for the treatment of patients with hypertension and type 2 diabetes nephropathy.
The initial dose of telmisartan is 40 mg once a day. If it does not have a blood pressure lowering effect, the dose can be slowly adjusted to 80 mg once a day. Generally, after taking the drug for 0.5-1 hours, the peak efficacy can be achieved, with a half life of more than 20 hours. After taking the drug for 4-8 weeks, the maximum blood pressure lowering effect can be achieved. The initial dose of irbesartan is 150 mg per day. If the antihypertensive effect is not good, it can be slowly adjusted to 300 mg per day. Generally, the drug reaches its peak efficacy after 1-1.5 hours of administration, with a half life of 11-15 hours. The maximum hypotensive effect is achieved after 4 to 6 weeks of continuous administration.
Telmisartan and irbesartan are both metabolized through the biliary tract and kidneys, so patients with liver and kidney dysfunction should pay attention when taking these two drugs, regularly monitor serum potassium and creatinine levels, and promptly adjust their medication in case of abnormalities.
The common adverse reactions of the two drugs are hypotension and hyperkalemia,
The information in this article comes from the Internet and is not used as treatment advice or investment advice. If this article has an impact on your rights and interests or is interested in this product, please contact us in time so that we can provide you with more help